Pamiparib for germline BRCA mutation-associated recurrent advanced ovarian, fallopian tube or primary peritoneal cancer [0.03%]
用于遗传性BRCA突变型复发性卵巢癌、输卵管癌或原发性腹膜癌患者的帕米帕利治疗
Anna Skrzypczyk-Ostaszewicz
Anna Skrzypczyk-Ostaszewicz
Epithelial ovarian cancers are gynecological malignancies with the poorest prognosis. Intensive research over the past few years has demonstrated ovarian cancer is a type of cancer in which new molecularly targeted drugs significantly affec...
Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma [0.03%]
倍林妥莫双抗：治疗套细胞淋巴瘤新突破
Anagha Deshpande,Yucai Wang,Javier Munoz et al.
Anagha Deshpande et al.
In July 2020, the U.S. Food and Drug Administration (FDA) approved brexucabtagene autoleucel (BA), the first anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for the treatment of relapsed/refractory mantle cell lymphoma (MCL). The p...
Maria Alexandra Rodrigues,Egídio Freitas,Tiago Torres
Maria Alexandra Rodrigues
Psoriasis is a chronic, immune-mediated, inflammatory skin disease, affecting 1% to 3% of the population in Western countries. Due to advances in the understanding of psoriasis pathogenesis, in particular, the role of the interleukin-23 (IL...
Asparaginase Erwinia chrysanthemi for acute lymphoblastic leukemia and lymphoblastic lymphoma [0.03%]
用于急性淋巴细胞白血病和淋巴母细胞淋巴瘤的鹅膏草宁链霉菌酶
Congying Gao,Xiangyu Ma,Zifan Zhang et al.
Congying Gao et al.
Acute lymphoblastic leukemia (ALL) is a neoplastic disease characterized by the malignant proliferation of lymphoid cells in the blood and bone marrow. It accounts for approximately 75% of childhood leukemia. Lymphoblastic lymphoma (LBL) is...
Drug Information Association (DIA) Europe - 34th Annual Meeting (March 29-31, 2022 - Brussels, Belgium/Virtual) [0.03%]
第34届DIA欧洲年会(2022年3月29日-31日 比利时布鲁塞尔/线上)
Monia Tumminello
Monia Tumminello
The Drug Information Association (DIA) Europe held its 2022 annual meeting as a hybrid event, both as an in-person meeting in Brussels, Belgium, and as a virtual meeting. Many topics were discussed during this 3-day meeting, including the l...
Matthew W McCarthy
Matthew W McCarthy
Outpatient treatment options for mild to moderate COVID-19 are severely limited. While many therapeutic options have been proposed, very few have demonstrated the appropriate safety and efficacy to warrant approval by national or internatio...
Efficacy, safety and cost of gene therapy medicinal products in the U.S. and Europe [0.03%]
美国和欧洲上市的基因治疗药物的有效性、安全性和成本分析
Bander Balkhi
Bander Balkhi
Gene or advanced therapy medicinal products (ATMPs) are evolving innovative products that have recently been attracting medical and healthcare attention. ATMPs are offering advanced techniques in treating certain conditions, including rare ...
Xin Song,Ruyi Li,Hongwei Wang et al.
Xin Song et al.
Cervical cancer is one of the most common gynecological malignancies. At present, cytotoxic chemotherapeutic drugs and immunotherapy are the main therapeutic options for recurrent and metastatic cervical cancer. Tisotumab vedotin is an anti...
Breanna Taylor,Jaimie Cohen,Jennifer Tejeda et al.
Breanna Taylor et al.
Chronic graft-versus-host disease (cGvHD) is a multisystem disease that is diagnosed in up to 70% of patients following allogeneic hematopoietic cell transplantation. In cGvHD, the donor immune cells attack the patient's cells, resulting in...
Farva R Gondal,Jawad Bilal,C Kent Kwoh
Farva R Gondal
Tanezumab is a novel humanized IgG2 monoclonal antibody that works by selectively targeting, binding to and inhibiting nerve growth factor (NGF). NGF is upregulated in response to injury and inflammation, and preclinical data indicate it pl...